Zymogenetics, Inc.

Merck Serono S. A.

Ares Trading S.a.

Mayo Foundation for Medical Education and Research

Arnaud Ythier

Eric Sievers

Herve Broly

Maria Lopez-Bresnahan

Giampiero De Luca

Alain Munafo

Sharon J Busby

Stephen M Ansell

Ivan Nestorov

Jan Öhrström

The present invention provides methods and compositions for treatment of hyperproliferative disorders and cancers, including multiple myeloma and Waldenstr&#xf6;m's macroglobulinemia, comprising administering to a patient in need of the treatment a TACI-Ig fusion molecule in amount sufficient to suppress proliferation-inducing functions of BlyS and APRIL.

Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules

The present invention is related to the use of Cladribine for the preparation of a pharmaceutical formulation for the treatment of multiple sclerosis, especially relapsing-remitting multiple sclerosis or early secondary progressive multiple sclerosis, wherein the preparation is to be the orally administered and wherein re-treatments are possible.

Cladribine regimen for treating multiple sclerosis

The present invention provides methods and compositions for treatment of B-cell malignancies, including non-Hodgkin's lymphoma, comprising administering to a patient in need of the treatment a TACI-Ig fusion molecule in amount sufficient to suppress proliferation-inducing functions of BlyS and APRIL.

Methods for treating B-cell malignancies using a TACI-Ig fusion molecule

The present invention is related to the use of Cladribine for the preparation of a pharmaceutical formulation for the treatment of multiple sclerosis, especially relapsing-remitting multiple sclerosis or early secondary progressive multiple sclerosis, wherein the preparation is to be orally administered and wherein re-treatments are possible.

Growing community of inventors

Collex-Bossy, Switzerland

Arnaud Ythier